Prognostic significance of CD8+ T-cells density in stage III colorectal cancer depends on SDF-1 expression.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
05
03
2020
accepted:
21
12
2020
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
26
8
2021
Statut:
epublish
Résumé
Since colorectal cancer (CRC) remains one of the most common malignancies, a tremendous amount of studies keep taking place in this field. Over the past 25 years, a notable part of the scientific community has focused on the association between the immune system and colorectal cancer. A variety of studies have shown that high densities of infiltrating CD8+ T-cells are associated with improved disease-free and overall survival in CRC. Stromal cell-derived factor-1 (SDF-1) is a protein that regulates leukocyte trafficking and is variably expressed in several healthy and malignant tissues. There is strong evidence that SDF-1 has a negative prognostic impact on a variety of solid tumors. However, the existing data do not provide sufficient evidence that the expression of SDF-1 has an influence on CRC. Knowing nowadays, that the microenvironment plays a crucial role in the development of cancer, we hypothesized that the expression of SDF-1 in CRC could influence the prognostic significance of CD8+ T-cells, as an indicator of the essential role of the immune microenvironment in cancer development. Therefore, we explored the combined prognostic significance of CD8+ T-cell density and SDF-1 expression in a large CRC collective. We analyzed a tissue microarray of 613 patient specimens of primary CRCs by immunohistochemistry (IHC) for the CD8 + T-cells density and the expression of SDF-1 by tumor cells and tumor-infiltrating immune cells. Besides, we analyzed the expression of SDF-1 at the RNA level in The Cancer Genome Atlas cohort. We found that the combined high CD8+ T-cell infiltration and expression of SDF-1 shows a favorable 5-year overall survival rate (66%; 95% CI 48-79%) compared to tumors showing a high expression of CD8+ T-cell only (55%; 95% CI 45-64%; p = 0.0004). After stratifying the patients in nodal negative and positive groups, we found that the prognostic significance of CD8+ T-cell density in nodal positive colorectal cancer depends on SDF-1 expression. Univariate and multivariate Hazard Cox regression survival analysis considering the combination of both markers revealed that the combined high expression of SDF-1 and CD8+ T-cell density was an independent, favorable, prognostic marker for overall survival (HR = 0.34, 95% CI 0.17-0.66; p = 0.002 and HR = 0.45, 95% CI 0.23-0.89; p = 0.021, respectively). In our cohort there was a very weak correlation between SDF-1 and CD8+ T-cells (r
Identifiants
pubmed: 33436863
doi: 10.1038/s41598-020-80382-2
pii: 10.1038/s41598-020-80382-2
pmc: PMC7803998
doi:
Substances chimiques
CXCL12 protein, human
0
Chemokine CXCL12
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
775Références
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Eur J Cancer. 2009 Sep;45(14):2579-87
pubmed: 19646861
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2018 Jul 26;379(4):396-397
pubmed: 30044940
Ann Surg Oncol. 2007 Nov;14(11):3154-8
pubmed: 17653799
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Cancer Biomark. 2015;15(6):869-79
pubmed: 26406413
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Oncotarget. 2016 Sep 20;7(38):62006-62018
pubmed: 27542220
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
PLoS One. 2014 Mar 04;9(3):e90400
pubmed: 24594697
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376
Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
J Exp Med. 1996 Sep 1;184(3):1101-9
pubmed: 9064327
J Clin Pathol. 2007 Oct;60(10):1112-6
pubmed: 17182662
Br J Cancer. 2003 Aug 4;89(3):431-6
pubmed: 12888808
Oncotarget. 2015 Nov 10;6(35):37588-99
pubmed: 26439988
Br J Cancer. 2004 Nov 1;91(9):1711-7
pubmed: 15494715
Lancet Oncol. 2007 Jul;8(7):651-7
pubmed: 17613427
PLoS One. 2010 Dec 10;5(12):e14282
pubmed: 21179245
J Clin Pathol. 2008 May;61(5):561-9
pubmed: 18326017
J Clin Oncol. 2011 Feb 20;29(6):601-3
pubmed: 21245434
Br J Cancer. 2017 Jun 27;117(1):124-135
pubmed: 28535157
PLoS One. 2013 May 29;8(5):e64814
pubmed: 23734221
Dis Colon Rectum. 2017 Oct;60(10):999-1017
pubmed: 28891842
Oncoimmunology. 2015 May 29;4(12):e1050574
pubmed: 26587320
Hum Pathol. 2004 Jul;35(7):808-16
pubmed: 15257543
Lancet Oncol. 2017 Jul;18(7):849-851
pubmed: 28677562
Clin Exp Metastasis. 2012 Feb;29(2):101-10
pubmed: 22075627
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Am J Clin Pathol. 2009 Aug;132(2):202-10; quiz 307
pubmed: 19605814
Virchows Arch. 2016 Apr;468(4):463-71
pubmed: 26818832
Dis Markers. 2014;2014:792183
pubmed: 25609852
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Oncogene. 2016 Feb 18;35(7):816-26
pubmed: 25961926
Nat Rev Drug Discov. 2003 Dec;2(12):962-72
pubmed: 14654795
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Immunol Today. 2000 Dec;21(12):630-6
pubmed: 11114424
Cell Oncol (Dordr). 2017 Dec;40(6):609-619
pubmed: 28936810
Clin Cancer Res. 2004 Jul 1;10(13):4450-6
pubmed: 15240536
Tumour Biol. 2016 Jun;37(6):7441-52
pubmed: 26678887
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86
pubmed: 12626353